

From: Abogunde, Maryann
Sent: Monday, January 10, 2011 4:13 PM
To: crmidmr@aol.com
Cc: Gabriel, Sandra
Subject: Additional information for NRC license renewal, mail control 573304

Licensee: Rio Grande Nuclear, P.S.C.
License No: 52-31065-01
Docket No: 03036979
Control No: 573304

To: David Rhoe , Physics Consultant

Thank you for taking time out to speak with me and Sandy this afternoon. Per our conversation, below are the questions concerning Rio Grande Nuclear renewal license. Please provide the information below to Dr. Denis Ruiz for review as soon as possible, and ask him to respond before close of business on **Friday, January 14, 2011**.

This is in reference to your letter dated December 20, 2010 regarding renewal of Nuclear Regulatory Commission License No. 52-31065-01. In order to continue our review, we need the following additional information:

1. Previously submitted correspondence identified you as Owner and Chief Executive Officer of the facility. Please confirm that you have management control over licensed operations.
2. Please confirm that the name of the licensed organization is Rio Grande Nuclear, P.S.C., rather than Rio Grande Nuclear Medicine, and provide a copy of a business license or registration.
3. Item 1d of your letter stated that you and Dr. Melendez "reviewed the renewal application dated August 3, 2010 and we are not agree with all statements made in this application." Please confirm that you are in agreement with all statements made in this application.
4. Item 4 of your letter indicated that you will use iodine-131 under 10 CFR 35.300 at this facility and did not specify a possession limit.
 - a. Is it acceptable for this license to limit your use of 10 CFR 35.300 materials to oral administration of sodium iodide iodine-131 with a maximum possession limit of 200 millicuries?
 - b. Please confirm that administration of iodine-131 will be limited to patients who can be released under the provisions of 10 CFR 35.75.
5. On a detailed version of your facility diagram, please provide the drawing scale used, and indicate the position of each of the areas described below:
 - a. Storage of radiopharmaceuticals

- b. Storage of radioactive waste, including decay-in-storage prior to disposal as nonradioactive waste
- c. Preparation and dispensing of radiopharmaceuticals (e.g., lead glass L-block, etc.)
- d. Administration of dosages of iodine-131.

Also provide a detailed description of:

- a. Shielding for the dose storage, dose preparation, waste storage, and iodine-131 administration areas.
 - b. The areas surrounding your areas of use, including on the same level and above and below. This should include designation of exterior walls.
6. Please provide the current contact telephone number, fax number, and e-mail address for you and your Radiation Safety Officer.

In order to continue prompt review of your application, we request that you submit your written response to these items under Dr. Denis Ruiz's signature before close of business on Friday, January 14th, 2011.

Please reply to my attention at the Region I Office and refer to Mail Control No. 573304. Please note that you may not reply to this letter by return e-mail. Your reply must be in writing by letter or facsimile (610-337-5269). If you have any technical questions regarding this deficiency letter, please call Maryann Abogunde (610) 337-5090.

Thank you for assistance in this matter.

Sincerely,

Maryann O. N. Abogunde

Health Physicist

U.S. Nuclear Regulatory Commission - Region I

Division of Nuclear Materials Safety - Medical Branch

Tel: (610) 337-5090

Fax: (610) 337-5269

 maryann.abogunde@nrc.gov